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Greogry L. Moneta, MD, Section EditorPopulation-Based Study of Incidence and Outcome of Acute Aortic
Dissection and Premorbid Risk Factor Control: 10-Year Results
From the Oxford Vascular Study
Howard DPJ, Banerjee A, Fairhead JF, et al. Circulation 2013;127:2031-7.
Conclusions: Hospital-based registries likely underestimate not only
the incidence of acute aortic dissection but also its association with premor-
bid hypertension. The most signiﬁcant treatable condition leading to acute
aortic dissection remains uncontrolled hypertension.
Summary: Even with well-established treatment guidelines, acute
aortic dissection can have a high case fatality rate. However, little data on
risk factors, incidence, or outcome of acute aortic dissection are available,
and there is no prospective population-based study. Although abdominal
aortic aneurysm incidence of rupture appears to be declining (Darwood R
et al, J Vasc Surg 2012;56:8-13), trends with respect to acute aortic dissec-
tion are uncertain (Thrumurthy SG et al, BMJ 2012;344:d8290). The
authors note there have only been two studies of the epidemiology of aortic
dissection since 1980, and both were retrospective and used only routinely
collected diagnostic or mortality coding data. Neither study assessed pre-
morbid risk factors or functional outcome (Clouse WD et al, Mayo Clin
Proc 2004;79:176-80; and Olsson C et al, Circulation 2006;114:2611-8).
This study used the 92,728 patient population of Oxfordshire in the United
Kingdom to prospectively determine event rates, incidence, risk factors,
early case fatality, and long-term outcome of all cases of acute aortic dissec-
tion from 2002 to 2012. Data were collected as part of the Oxford Vascular
Study. Among 155 patients with 174 acute aortic events, there were 54
patients (31 men; mean age, 72.0 years) with 59 thoracoabdominal aortic
dissections (52 incident events: 6/100,000; 95% conﬁdence interval, 4-7)
comprising 37 Stanford type A and 15 Stanford type B. Of the patients
with type A incident events, 18 (48.6%) died before hospital assessment
(61.1% women). The 30-day fatality rate was 47.4% for patients with type
A dissections who survived to hospital admission and 13.3% for patients
with type B dissections. Subsequent 5-year survival rates were, however,
high (85.7% for type A; 83.3% for type B). Although 67.3% of patients
were taking antihypertensive drugs, 46.0% had at least one systolic BP
>180 mm Hg in their primary care records during the preceding 5 years.
The proportion of blood pressures in the hypertensive range (>140/90
mmHg) averaged 56.0%. Premorbid blood pressure in the type A dissection
patients was higher in those patients where the dissection was immediately
fatal than in those who survived to admission (mean/standard deviation
pre-event systolic blood pressure was 151.2 6 19.3 vs 137.9 6 17.9;
P < .001).
Comment: The data suggest that the incidence of acute aortic dissec-
tion is higher than previously reported. The authors speculate this is likely
due to more complete inclusion of deaths before hospital admission. If
one does the numbers in the report, it appears there are w44 ruptured
abdominal aortic aneurysms per year and 24 acute aortic dissections per
year in the Oxford population ofw93,000 patients. The Oxford population
is 94% Caucasian, whereas that of the United States is about 72.4% Cauca-
sian, and thus, the incidence rates of acute aortic events in this study are not
directly applicable to all populations. Nevertheless, the epidemiologic data
provided here allow one to estimate the burden of acute aortic events in
many regions of Europe, Australia, and the United States.
Cilostazol Reduces Angiographic Restenosis After Endovascular
Therapy for Femoropopliteal Lesions in the Sufﬁcient Treatment of
Peripheral Intervention by Cilostazol Study
Iida O, Yokoi H, Soga Y, et al., and the STOP-IC investigators. Circulation
2013;127:2307-15.
Conclusions: Cilostazol reduces angiographic restenosis for femoro-
popliteal lesions after percutaneous transluminal angioplasty with provi-
sional nitinol stenting.
Summary: Use of nitinol stents has improved long-term outcomes of
endovascular therapy for femoropopliteal lesions compared with balloon
angioplasty alone (Schillinger M et al, N Engl J Med 2006;354:1879-88;
and Laird JR et al, Circ Cardiovasc Interv 2010;3:267-76). However,
even with the use of stents, there remains a 20% to 50% incidence of reste-
nosis at 1 year. The present study was designed to determine, usingangiographic follow-up, whether treatment with cilostazol reduces resteno-
sis at 12 months after percutaneous transluminal angioplasty with provi-
sional nitinol stenting. The Sufﬁcient Treatment of Peripheral
Intervention by Cilostazol study enrolled 200 patients with femoropopliteal
lesions. Patients were treated from March 2009 to April 2011 at 13 centers
and randomly assigned 1:1 to receive oral aspirin with or without cilostazol.
The primary end point was 12-month angiographic restenosis of $50%.
Secondary end points were restenosis rates on duplex ultrasound imaging
(peak systolic velocity >200 cm/s), rates of major adverse cardiac events,
and target lesion event-free survival. End points were assessed in a blinded
fashion. The mean lesion length and reference vessel diameter at the treated
segment were 128 6 86 mm and 5.4 6 1.4 mm, respectively. Frequency of
stent use was similar between groups (88% vs 90% in the cilostazol and non-
cilostazol groups, respectively; P ¼ .82). Eleven patients died, and 152
(80%) had evaluable angiographic data at 12 months of follow-up. Angio-
graphic restenosis at 12 months was 20% (15 of 75) in the cilostazol group
vs 49% (38 of 77) in the noncilostazol group (P ¼ .0001) by intention-to-
treat analysis. There was also a signiﬁcantly higher event-free survival in the
cilostazol group at 12 months (83% vs 71%, P ¼ .02). Cardiovascular event
rates were similar in both groups.
Comment: The data indicate cilostazol, in combination with aspirin,
can signiﬁcantly reduce angiographic restenosis after endovascular therapy
for femoropopliteal disease. This study is limited by the fact that, strictly
speaking, the data apply only to a Japanese population. At the start of the
study, the S.M.A.R.T. stent was the only one available for this study.
Newer-generation stents and drug-eluting stents were not included.
Certainly, restenosis rates with the use of cilostazol and newer stents or clo-
pidogrel, or both, in more varied populations will also be of interest. Until
such data are available, routine addition of cilostazol as an adjunct to fem-
oropopliteal stenting is not likely to occur.
Home-Based Walking Exercise Intervention in Peripheral Artery
Disease a Randomized Clinical Trial
McDermott MM, Liu K, Guralnik JM, et al. JAMA 2013;310:57-65.
Conclusions: Home-based walking exercise programs can signiﬁ-
cantly improve walking endurance, physical activity, and patient-perceived
walking endurance and speed in patients with peripheral arterial disease
(PAD), with and without classic claudication symptoms.
Summary: Few patients with PAD participate in supervised treadmill
exercise therapy (Regensteiner JG, Curr Drug Targets Cardiovasc Haematol
Disord 2004;4:233-9). There may be many reasons why supervised exercise
therapy is not used in the PAD patient, including that it requires regular
transportation to an exercise center and that supervised exercise is not
generally covered by medical insurance. Although home-based walking
exercise would seem a promising alternative to supervised exercise, trials
have yielded conﬂicting results with respect to the efﬁcacy of home-based
exercise in the PAD patient. Indeed, most physicians do not recommend
home-based walking exercise to patients with PAD (Hirsch AT et al, Vasc
Med 2001;6:87-96; and McDermott MM et al, J Gen Intern Med
2002;17:895-904). Here, the authors report the result of the Group
Oriented Arterial Leg Study, a randomized, controlled, clinical trial
designed to assess if an intervention to increase home-based walking exercise
would improve walking performance at the 6-month follow-up in patients
with PAD. A group-mediated cognitive behavioral intervention incorpo-
rating group support and self-regulatory skills was used to help participants
adhere to a home-based exercise program. The authors’ hypothesis was that
the intervention group would have greater improvement in objective and
subjective measures of walking performance and physical activity compared
with a control group that received health education alone. The study
included 194 patients with PAD, 72.2% of whom did not have classic symp-
toms of intermittent claudication. The study took place in Chicago between
July 22, 2008, and December 14, 2012. Randomization was to one of two
parallel groups, a home-based group-mediated cognitive behavioral walking
intervention or an attention control condition. The primary outcome was
the 6-month change in 6-minute walk performance. The secondary
outcomes included the 6-month change in treadmill walking, physical
activity, Walking Impairment Questionnaire, and Physical and Mental1423
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Those randomized to the intervention group increased their 6-minute
walk distance in meters signiﬁcantly (357.4 to 399.8 vs 353.3 to 342.2
for those in the control group; mean difference, 53.5; P < .001). There
were also increases in maximum treadmill walking time (intervention,
7.91 to 9.44 minutes vs control, 7.56 to 8.09 minutes; mean difference,
1.01 minutes; P ¼ .04). Accelerometer-measured physical activity over 7
days also increased in the intervention group vs the control group (P ¼
.03). There were also signiﬁcant improvements in the Walking Impairment
Questionnaire distance score (P ¼ .003) and Walking Impairment Ques-
tionnaire speed score (P ¼ .004).
Comment: The study indicates that home-based exercise can be
effective in patients with PAD. It does not indicate that home-based exercise
has equal effectiveness to supervised exercise programs, because the two
were not directly compared. Nevertheless, until supervised exercise becomes
a beneﬁt of insurance coverage, the data should encourage physicians to
recommend home-based exercise therapy in their patients with PAD.
Use of Glucocorticoids and Risk of Venous Thromboembolism: A
Nationwide Population-Based Case-Control Study
Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. JAMA Intern
Med 2013;173:743-52.
Conclusions: Glucocorticoid use increases the risk of venous throm-
boembolism (VTE).
Summary: It is known that excess endogenous cortisol increases VTE
risk. Whether this risk applies to exogenous use of glucocorticoids is
unclear, however, potentially clinically important. The authors point out
that in Denmark, the country of origin of this study, 3.5% of the population
redeemed a prescription for systemic glucocorticoids in 2010 (Danish
Medicines Agency). Given the incidence of VTE and the prevalence of
glucocorticoid use, any association between VTE and glucocorticoid use
has important implications. The authors therefore decided to examine the
association between exogenous glucocorticoid use and VTE. This was
a population case-control study using a nationwide database from
Denmark. The authors identiﬁed 38,765 VTE cases from the period of
January 1, 2005, through December 31, 2011. Risk matched sampling
by birth year and sex was used to select 387,650 controls from the general
population. The VTE diagnosis date for the case was the index date for
cases and matched controls. Patients who had ﬁlled a glucocorticoid
prescription were classiﬁed by the time the prescription was ﬁlled, #90
days, 91 to 365 days, and >365 days before the index VTE date. Such
patients were classiﬁed as present, recent, and former users of glucocorti-
coids, respectively. Present users were subdivided into new (ﬁrst-ever
prescription <90 days before the index date) and continuing users (others).
Analysis was performed using conditional logistic regression adjusted for
VTE risk factors to estimate incidence rate ratios (IRRs) and 95% conﬁ-
dence intervals (CIs) for glucocorticoid users vs nonusers. VTE risk was
increased by systemic glucocorticoids in present (adjusted IRR, 2.31; 95%
CI, 2.18-2.45), new (3.06; 2.77-3.38), continuing (2.02; 1.88-2.17),
and recent (1.18; 1.10-1.26) users but not in former users (0.94; 0.90-
0.99). Adjusted IRR increased from 1.00 (95% CI, 0.93-1.07) for a prednis-
olone-equivalent cumulative dose of #10 mg to 1.98 (95% CI, 1.78-2.20)
for >1000 to 2000 mg, and to 1.60 (95% CI, 1.49-1.71) for doses >2000
mg. New use of inhaled (adjusted IRR, 2.21; 95% CI, 1.72-2.86) and intes-
tinal-acting (adjusted IRR, 2.17; 95% CI, 1.27-3.71) glucocorticoids also
increased VTE risk.
Comment: Of course, many of the disease processes for which gluco-
corticoids are prescribed may, in themselves, increase VTE risk. However,
this extensive analysis found increased risk for not only systemic glucocorti-
coids but also inhaled and intestinal-acting glucocorticoids, and a causal link
is further suggested by higher risk with new users, and with higher doses.
These observations, along with adjustment for confounding variables,
strongly suggest that the authors’ conclusion is correct that glucocorticoid
use increases the risk of VTE.
Ambulatory Blood Pressure Changes After Renal Sympathetic
Denervation in Patients with Resistant Hypertension
Mahfoud F, Ukena C, Schmieder RE, et al. Circulation 2013;124:132-40.
Conclusions: Ofﬁce blood pressures are reduced and relevant aspects
of ambulatory blood pressure (BP) monitoring (APBM) are improved after
renal sympathetic denervation in patients with true-treatment resistant
hypertension.
Summary: Hypertensive patterns and methods of assessing BP appear
to be important in the relationship between hypertension and cardiovascular
morbidity and mortality. Guidelines recommend ABPM for patients with
resistant hypertension. This is to exclude pseudohypertension and accurately
assess BP control according to treatment. ABPM, with 24-hour day-and-night average BP values, correlates better than ofﬁce BP values with hyper-
tensive or diabetic end-organ damage (Mancia G et al, Hypertension
2000;36:894-900). In addition, nighttime BP correlates more closely
with cardiovascular morbidity and mortality than daytime BP (Fagard RH
et al, Hypertension 2008;51:55-61). Finally, high nighttime BP and non-
dipping patterns of hypertension have been associated with increased
sympathetic activity in hypertensive patients (Grassi G et al, Hypertension
2008;52:925-31). Renal sympathetic denervation (RDN) reduces ofﬁce
systolic and diastolic BPs in patients with resistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). The purpose of this study was to
investigate the effects of RDN on out-of-ofﬁce BP using 24-hour ABPM.
The study represents the largest cohort of patients with true resistant and
pseudoresistant hypertension analyzed thus far. A total of 346 uncontrolled
hypertensive patients were separated according to daytime ambulatory BP
monitoring into 303 with true resistant BP (ofﬁce systolic BP [SBP] 172
6 22 mm Hg; 24-hour SBP 154 6 16 mm Hg) and 43 with pseudoresist-
ant hypertension (ofﬁce SBP 161 6 20.3 mm Hg; 24-hour SBP 121 6 20
mm Hg). Patients were from 10 centers and were studied at 3, 6, and 12
months of follow-up after RDN. In follow-up, ofﬁce SBP was reduced by
21.5/23.7/27.3 mm Hg, ofﬁce diastolic BP by 8.9/9.5/11.7 mm Hg,
and pulse pressure by 13.4/14.2/14.9 mm Hg (n ¼ 245/236/90; P for
all <.001), respectively, at 3, 6, and 12 months. In patients with true treat-
ment resistance, there was a signiﬁcant reduction with RDN in 24-hour SBP
(0.1/10.2/11.7) and minimum SBP (6.0/9.4/13.1 mm Hg; P
< .001) at 3, 6, and 12 months, respectively. In pseudoresistant patients,
RDN had no effect on ambulatory BP; however, ofﬁce BP was reduced
to a similar extent. RDN was equally effective in reducing BP in different
subgroups of patients. Ofﬁce SBP at baseline was the only independent
correlate of BP response.
Comment: The study addressed concerns that RDN might not as
effectively reduce ambulatory BP as it does ofﬁce BP. Results of the study
are not entirely unexpected. The Symplicity study of resistant hypertension
and RDN did not speciﬁcally exclude pseudoresistant hypertension (Esler
MD et al, Lancet 2010;376:1903-9). However, only w12% of the patients
in the Symplicity study apparently had pseudoresistant hypertension. As
treatment with RDN for resistant hypertension potentially moves toward
application out of clinical trials, it will be important for clinicians to be aware
that only patients with truly resistant hypertension, and not those with
“white-coat syndrome,” be considered for RDN.
Endovascular Repair Versus Open Repair of Ruptured Abdominal
Aortic Aneurysms: A Multicenter Randomized Controlled Trial
Reimerink JJ, Hoornweg LL, Vahl AC, and the Amsterdam Acute
Aneurysm Trial Collaborators. Ann Surg 2013;258:248-56.
Conclusions: There is no difference in outcome of treatment of
ruptured abdominal aortic aneurysm (RAAA) in rates of death and severe
complication for those patients treated with endovascular (EVAR) or
open repair (OR).
Summary: In recent years, treatment of RAAA with EVAR has
emerged as an alternative to OR. Support for the hypothesis that EVAR
reduces mortality in patients with RAAA vs those treated with OR comes
from observational and population-based studies (Veith FJ, Ann Surg
2009;250:818-24; and Giles KA, J Endovasc Ther 2009;16:554-64).
However, to date, no signiﬁcant randomized trial data has been available
comparing EVAR vs OR for RAAA. A single previous trial was terminated
after randomizing 32 patients (Hinchliffe RJ et al, Eur J Vasc Endovasc Surg
2006;32:506-13). The Amsterdam Acute Aneurysm Trial was designed
with the hypothesis that EVAR would reduce mortality and severe compli-
cations compared with OR for treatment of RAAA. The study was conduct-
ed in the greater Amsterdam area (1.24 million inhabitants and 10
hospitals). Three hospitals, consisting of two academic medical centers
and a teaching hospital, were trial centers for this study. The trial centers
provided alternating around-the-clock RAAA service. The other seven
regional hospitals agreed to participate in the trial by transferring patients
with suspected RAAA to one of the trial centers if possible. They also
provided data on all patients who presented with an RAAA. After diagnosis,
anatomic suitability for EVAR based on computed tomography angiog-
raphy and clinical suitability for OR was documented by the vascular
surgeon and the radiologist. Patients suitable for both were then random-
ized. All patients in the trial region with proven RAAA were included in
a prospective parallel cohort. The primary end point of the study was the
composite of death and severe complications at 30 days. Between April
2004 and February 2011, 520 patients were identiﬁed with RAAA. Of these
patients, 365 were excluded from potential randomization because of
anatomy unfavorable for EVAR, another 71 were not evaluated by
computed tomography scan, and 54 were not referred to a trial center.
This left 155 with favorable anatomy who could potentially be randomized.
An additional 39 patients, however, were excluded as unﬁt for OR (n ¼ 16),
